<html xmlns:v="urn:schemas-microsoft-com:vml"
      xmlns:o="urn:schemas-microsoft-com:office:office"
      xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page2_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page2_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>19</o:Revision>
  <o:TotalTime>454</o:TotalTime>
  <o:Created>2006-08-23T16:14:00Z</o:Created>
  <o:LastSaved>2006-09-01T13:44:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>811</o:Words>
  <o:Characters>4627</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>38</o:Lines>
  <o:Paragraphs>9</o:Paragraphs>
  <o:CharactersWithSpaces>5682</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	font-style:italic;}
h3
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:navy;
	font-weight:normal;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1030"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:139.5pt;
 height:45pt'>
 <v:imagedata src="./Page2_files/image001.png" o:title="InterPro"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=186 height=60
src="./Page2_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy'>Amyloid-</span><span style='font-size:
28.0pt;mso-bidi-font-size:16.0pt;font-family:Symbol;color:navy'>b</span><span
style='font-size:28.0pt;mso-bidi-font-size:16.0pt;color:navy'> Precursor Protein<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:navy'>Amyloid
Plaque Formation <o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr>
  <td width=568 valign=top style='width:426.1pt;background:#B3B3B3;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoNormal align=center style='text-align:center'><!--[if gte vml 1]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:414.75pt;height:283.5pt'>
   <v:imagedata src="./Page2_files/image003.png" o:title="APP_Amyloid_Plaque_complete"/>
  </v:shape><![endif]--><![if !vml]><img border=0 width=553 height=378
  src="./Page2_files/image004.jpg" v:shapes="_x0000_i1026"><![endif]></p>
  <p class=MsoNormal align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  </td>
 </tr>
 <tr>
  <td width=568 valign=top style='width:426.1pt;background:#DADEF2;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><u>APP Processing</u>:<span
  style="mso-spacerun: yes">  </span><span style='font-family:Symbol'>a</span>-secretase
  and <span style='font-family:Symbol'>g</span>-secretase produce non-plaque
  forming p3, while <span style='font-family:Symbol'>b</span>-secretase and <span
  style='font-family:Symbol'>g</span>-secretase produce amyloid plaque-forming
  A<span style='font-family:Symbol'>b</span>.<span style="mso-spacerun: yes"> 
  </span>The different regions of the APP protein are indicated.</p>
  </td>
 </tr>
</table>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>APP can
be processed in different ways by different sets of enzymes - one pathway leads
to amyloid plaque formation (amyloidogenic), while another does not
(non-amyloidogenic).<span style="mso-spacerun: yes">  </span>Usually about 90% of
APP enters the non-amyloidogenic pathway, and 10% the amyloidogenic one, but
these ratios can change due to mutations, environmental factors, as well as the
age of the individual.<span style="mso-spacerun: yes">  </span>Cleavage
products from both these pathways may play important roles in neural
development and function.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3>Non-Plaque-forming (non-amyloidogenic) Pathway </h3>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>In the
non-plaque-forming pathway, APP is cleaved first by <span style='font-family:
Symbol'>a</span>-secretase to yield a soluble N-terminal fragment (sAPP<span
style='font-family:Symbol'>a</span>) and a C-terminal fragment (CTF<span
style='font-family:Symbol'>a</span>).<span style="mso-spacerun: yes"> 
</span>sAPP<span style='font-family:Symbol'>a</span> may be involved in the
enhancement of synaptogenesis, neurite outgrowth and neuronal survival, and are
considered to be neuroprotective.<span style="mso-spacerun: yes">  </span>CTF<span
style='font-family:Symbol'>a</span> is retained in the membrane, where it is
acted upon by presenilin-containing <span style='font-family:Symbol'>g</span>-secretase
to yield a soluble N-terminal fragment (p3) and a membrane-bound C-terminal
fragment (AICD, or APP intracellular domain).<span style="mso-spacerun: yes"> 
</span>AICD may be involved in nuclear signalling via transcriptional
regulation as well as axonal transport through its ability to associate with a
host of different proteins.</p>

<p class=MsoNormal style='text-indent:36.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3>Plaque-forming (amyloidogenic) Pathway </h3>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>In the
plaque-forming pathway, APP is cleaved first by a different enzyme, <span
style='font-family:Symbol'>b</span>-secretase (a transmembrane aspartic
protease), yielding a soluble N-terminal fragment (sAPP<span style='font-family:
Symbol'>b</span>) and a membrane-bound C-terminal fragment (CTF<span
style='font-family:Symbol'>b</span>).<span style="mso-spacerun: yes"> 
</span>This cut is made closer to the N-terminal end of APP than with <span
style='font-family:Symbol'>a</span>-secretase, making CTF<span
style='font-family:Symbol'>b</span> longer than CTF<span style='font-family:
Symbol'>a</span>.<span style="mso-spacerun: yes">  </span>CTF<span
style='font-family:Symbol'>b</span> is then acted upon by <span
style='font-family:Symbol'>g</span>-secretase (as occurred in the previous
pathway), yielding a membrane-bound C-terminal fragment (AICD) the same as
before, and a soluble N-terminal fragment (amyloid-<span style='font-family:
Symbol'>b</span>, or A<span style='font-family:Symbol'>b</span>) that is longer
than p3.<span style="mso-spacerun: yes">  </span>Though A<span
style='font-family:Symbol'>b</span> is required for neuronal function, it can
accumulate in the extracellular space of the brain, where it can aggregate to
form amyloid plaques.<span style="mso-spacerun: yes">  </span>A<span
style='font-family:Symbol'>b</span> can exert deleterious effects on neuronal
and synaptic function, ultimately causing neuronal cell death.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3>Plaque Formation </h3>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>A<span
style='font-family:Symbol'>b</span> is stickier than other APP fragments, and
accumulates by stages into microscopic plaques.<span style="mso-spacerun:
yes">  </span>Plaques form by a multi-step polymerisation mechanism, with A<span
style='font-family:Symbol'>b</span> peptides aggregating into oligomers, which
cluster together to form fibrils with a regular <span style='font-family:Symbol'>b</span>-sheet
structure.<span style="mso-spacerun: yes">  </span>These fibrils adhere
together to form mats, which clump together with other substances to finally
form plaques.<span style="mso-spacerun: yes">  </span>A<span style='font-family:
Symbol'>b</span> plaques may disrupt brain cells by clogging points of
cell-cell communication, as well as activating immune cells that trigger
inflammation, which can be lethal to cells.<span style="mso-spacerun: yes"> 
</span>In addition, A<span style='font-family:Symbol'>b</span> is thought to
cause oxidative damage to cells.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3>Alzheimers Disease </h3>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>A<span
style='font-family:Symbol'>b</span> is not all bad.<span style="mso-spacerun:
yes">  </span>Soluble A<span style='font-family:Symbol'>b</span> oligomers are
required for A<span style='font-family:Symbol'>b</span>-induced inhibition of
long-term-potentiation.<span style="mso-spacerun: yes">  </span>However, the
insoluble amyloid plaques appear to disrupt neuronal function.<span
style="mso-spacerun: yes">  </span>The problem may have to do with the
aggregation state of the peptide, which in turn may be influenced by the
concentration, structure and length of A<span style='font-family:Symbol'>b</span>
peptide present.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>The
concentration of A<span style='font-family:Symbol'>b</span> in the
extracellular space may affect its toxicity by influencing its
aggregation.<span style="mso-spacerun: yes">  </span>A<span style='font-family:
Symbol'>b</span> concentration appears to be influenced by several factors,
including the level of neural activity and synaptic release, which seem to
increase A<span style='font-family:Symbol'>b</span> levels.<span
style="mso-spacerun: yes">  </span>Age could also play a factor, studies
showing that the level of <span style='font-family:Symbol'>a</span>-secretase
decreases with age, while <span style='font-family:Symbol'>b</span>-secretase
activity appears to increase.<span style="mso-spacerun: yes">  </span>In
addition, studies indicate that cholesterol may play a role in regulating A<span
style='font-family:Symbol'>b</span> production, with high levels of cholesterol
being linked with increased A<span style='font-family:Symbol'>b</span> release
and plaque formation.<span style="mso-spacerun: yes">  </span>One possible
explanation for this result is the presence of cholesterol-rich regions of
membranes known as lipid rafts, which may affect the distribution of
APP-cleaving enzymes.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>The structure
of the A<span style='font-family:Symbol'>b</span> oligomers could influence
plaque formation.<span style="mso-spacerun: yes">  </span>Whereas soluble
monomeric A<span style='font-family:Symbol'>b</span> peptide has been shown to
have an unordered structure in solution, within amyloid fibrils A<span
style='font-family:Symbol'>b</span> adopts a regular <span style='font-family:
Symbol'>b</span>-sheet conformation.<span style="mso-spacerun: yes"> 
</span>The conformational change to a <span style='font-family:Symbol'>b</span>-sheet
structure may trigger the formation of the abnormal fibrillar amyloid plaques
found in AD patients.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>A<span
style='font-family:Symbol'>b</span> peptides can differ in length from 38 to 42
amino acids.<span style="mso-spacerun: yes">  </span>A<span style='font-family:
Symbol'>b</span> ending at amino acid 42 (A<span style='font-family:Symbol'>b</span><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>42</span>) appears to be the
main species of A<span style='font-family:Symbol'>b</span> peptide deposited in
plaques.<span style="mso-spacerun: yes">  </span>In AD patients, studies show
an increase in the ratio of A<span style='font-family:Symbol'>b</span><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>42</span> to A<span
style='font-family:Symbol'>b</span><span style='font-size:10.0pt;mso-bidi-font-size:
12.0pt'>40</span>.<span style="mso-spacerun: yes">  </span>In addition, genetic
changes involved in familial AD result in increased amounts of A<span
style='font-family:Symbol'>b</span><span style='font-size:10.0pt;mso-bidi-font-size:
12.0pt'>42</span> present in the brain.<span style="mso-spacerun: yes"> 
</span>A<span style='font-family:Symbol'>b</span> peptides are metal chelators
with the ability to reduce those metals.<span style="mso-spacerun: yes"> 
</span>For example, <i>in vitro</i>, A<span style='font-family:Symbol'>b</span>
can reduce Cu<sup>2+</sup> to Cu<sup>+</sup>, and Fe<sup>3+</sup> to Fe<sup>2+</sup>.<span
style="mso-spacerun: yes">  </span>A<span style='font-family:Symbol'>b</span><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>42</span> appears to be a
more effective reductant than A<span style='font-family:Symbol'>b</span><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>40</span>, which may
contribute to the ability of A<span style='font-family:Symbol'>b</span><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>42</span> to activate
mononuclear phagocytes in the brain and elicit an inflammatory response.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Therefore, it
appears that there may be several contributory factors to plaque formation in
AD patients, the relative importance of which still need to be deciphered.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page3.htm" title="Page 3">What InterPro Tells Us</a><o:p></o:p></span></h2>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Previous:<span
style="mso-spacerun: yes">  </span><a href="Page1.htm" title="Page 1">Amyloid-<span
style='font-family:Symbol'>b</span> Precursor Protein, Still and Enigma</a></span><span
style='font-style:normal'><o:p></o:p></span></h2>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
